Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012

2016 ◽  
Vol 96 (3) ◽  
pp. 355-362 ◽  
Author(s):  
Luiz Claudio Santos Thuler ◽  
Maria S. Pombo-de-Oliveira
Keyword(s):  
Cancer Registry ◽  
Acute Promyelocytic Leukaemia ◽  
Promyelocytic Leukaemia ◽  
Registry Study ◽  
Acute Myeloid

scholarly journals MicroRNAs as Potential Biomarkers in Acute Promyelocytic Leukaemia

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Imilia Ismail ◽  
Sarina Sulong ◽  
Rosline Hassan
Keyword(s):  
Acute Promyelocytic Leukaemia ◽  
Growth And Development ◽  
Clinical Characteristics ◽  
Promyelocytic Leukaemia ◽  
Biological Processes ◽  
Differentiation Block ◽  
M3 Subtype ◽  
Acute Myeloid ◽  
Potential Biomarkers ◽  
New Discovery

Acute promyelocytic leukaemia (APL) is an M3 subtype of acute myeloid leukaemia (AML). This classification is based on the morphology of promyelocytic cell. The clinical characteristics of APL can be recognized by haemorrhagic episodes, a differentiation block at the promyelocytic stage, and sensitivity to the differentiation response to all-trans-retinoic acid (ATRA). Cytogenetically, APL is characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the production of PML/RARα fusion protein. Recent studies reported that microRNAs (miRNAs) have also been proposed to contribute to the pathogenesis of APL. miRNAs have been associated with the pathogenesis of cancer and their involvement as oncogenic and tumour suppressor activities have been identified. They are involved in various biological processes including the cell proliferation, differentiation, growth and development, metabolism, apoptosis, and haematopoiesis. The new discovery of miRNAs as possible therapeutic markers will provide new insight for the diagnosis and therapeutic entries for the treatment of APL. This review highlights the potential of miRNAs as biomarkers in APL.

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required

2009 ◽  
Vol 15 (11) ◽  
pp. 1303-1310 ◽  
Author(s):  
Ana M Pascual ◽  
Neus Téllez ◽  
Isabel Boscá ◽  
Javier Mallada ◽  
Antonio Belenguer ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Acute Promyelocytic Leukaemia ◽  
Promyelocytic Leukaemia ◽  
Incidence Density ◽  
Multiple Sclerosis Population ◽  
Reported Data ◽  
Secondary Leukaemia ◽  
Acute Myeloid

The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature. Six new cases of acute myeloid leukaemia were observed by prospectively following two Spanish series of 142 and 88 patients with worsening relapsing multiple sclerosis and secondary-progressive disease treated with mitoxantrone. A literature review shows 32 further cases of acute myeloid leukaemia reported, 65.6% of which are therapy-related acute promyelocytic leukaemia. Five cases in the cohorts fulfilled the diagnostic criteria for acute promyelocytic leukaemia, and one patient was diagnosed with pre-B-acute lymphoblastic leukaemia. Acute myeloid leukaemia latency after mitoxantrone discontinuation was 1 to 45 months. The accumulated incidence and incidence density was 2.82% and 0.62%, respectively, in the Valencian cohort, and 2.27% and 0.44% in the Catalonian cohort. In the only seven previously reported series, the accumulated incidence varied from 0.15% to 0.80%. The real incidence of acute myeloid leukaemia after mitoxantrone therapy in the multiple sclerosis population could be higher as evidenced by the growing number of cases reported. Haematological monitoring should continue for at least 5 years after the last dose of mitoxantrone. These data stress the necessity of re-evaluating this risk.

Sign in / Sign up

Export Citation Format

Share Document